Systemic pain relief after omalizumab injection in patient with hypermobile Ehlers–Danlos syndrome: A case report

Abstract

Key Clinical Message Omalizumab may be a beneficial adjunct treatment option for hEDS patients require to improve pain control, ability to perform ADLs and functionality and social engagement, and most importantly, quality of life.

Keywords

• chronic pain
• hypermobile Ehlers–Danlos syndrome
• omalizumab
• physical medicine and rehabilitation
• quality of life